Discounted Cash Flow (DCF) Analysis Levered

CytomX Therapeutics, Inc. (CTMX)

$1.41

+0.01 (+0.71%)
All numbers are in Millions, Currency in USD

Free Cash Flow

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue 71.6259.5057.49100.3669.5773.6878.0282.6287.5092.66
Revenue (%)
Operating Cash Flow 170.37-75.52-140.485.26-119.03-44.10-46.70-49.45-52.37-55.46
Operating Cash Flow (%)
Capital Expenditure -1.56-3.79-3.50-2.31-1.61-2.83-3-3.18-3.37-3.57
Capital Expenditure (%)
Free Cash Flow 168.81-79.31-143.982.95-120.64-46.93-49.70-52.63-55.73-59.02

Weighted Average Cost Of Capital

Share price $ 1.41
Beta 0.469
Diluted Shares Outstanding 46.15
Cost of Debt
Tax Rate 0.00
After-tax Cost of Debt -%
Risk-Free Rate
Market Risk Premium
Cost of Equity 6.178
Total Debt 21.67
Total Equity 65.07
Total Capital 86.74
Debt Weighting 24.99
Equity Weighting 75.01
Wacc

Build Up Free Cash Flow

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue 71.6259.5057.49100.3669.5773.6878.0282.6287.5092.66
Operating Cash Flow 170.37-75.52-140.485.26-119.03-44.10-46.70-49.45-52.37-55.46
Capital Expenditure -1.56-3.79-3.50-2.31-1.61-2.83-3-3.18-3.37-3.57
Free Cash Flow 168.81-79.31-143.982.95-120.64-46.93-49.70-52.63-55.73-59.02
WACC
PV LFCF -----
SUM PV LFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) -
Free cash flow (t + 1) -60.20
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt -183.86
Equity Value -
Shares Outstanding 46.15
Equity Value Per Share -